| Market Cap | ₹133.36 CrSmall Cap |
|---|---|
| TTM Revenue | ₹165.96 CrOperating Income |
| ROE Annual | 32.46%High Efficiency |
| Day RSI | 71.72Overbought Zone |
Key highlights
- New Lung Care Tablets target urban consumers exposed to air pollution and smoking
- Entry into the Indian respiratory healthcare segment valued at ₹18,912.64 crore
- Formula combines N-Acetyl Cysteine (NAC) with Vasaka Extract and Quercetin
- India accounts for 30.28 percent of global deaths from respiratory diseases
- Company reported annual revenue growth of 115.42 percent in the latest fiscal year
The Product — What It Is
Aayush Lung Care Tablets are formulated as a daily wellness solution integrating science-backed nutraceuticals with traditional herbal extracts. The product features a combination of N-Acetyl Cysteine (NAC), Vasaka Extract, Licorice, and Quercetin, supported by Vitamin C, Vitamin D2, and Zinc. It is specifically designed to support healthy airway function, provide antioxidant and immune support, and maintain overall lung health.
This launch targets a growing demographic of consumers in urban centers who face high levels of environmental stress, including air pollution and occupational pollutants, alongside those seeking respiratory recovery after viral complications.
Commercial Opportunity
- The Indian respiratory system therapeutic segment recorded sales of ₹18,912.64 crore in 2025
- Market growth is trending at approximately 10 percent year-on-year from ₹17,199.40 crore in 2024
- India represents 15.69 percent of global chronic respiratory disease cases
- Strategic focus on the emerging preventive respiratory-wellness category to build a differentiated position
- Addressing a critical health burden where India accounts for nearly one-third of global respiratory deaths
Strategic Fit and Business Overview
The introduction of Lung Care Tablets represents a natural progression from the company’s existing Aayush Herbal Masala, which targeted health risks associated with smokeless tobacco. Aayush Wellness is building a health-risk-led portfolio to create cross-selling opportunities across its existing consumer base in the preventive healthcare space. Established in 1984 and ISO 9000/22000 certified, the company focuses on merging traditional wellbeing with modern innovation.
This expansion into the respiratory category strengthens its presence in the nutraceutical landscape, aiming to enhance long-term value through products that address high-prevalence health challenges.
Financial Context
Aayush Wellness has demonstrated significant top-line expansion, with TTM operating revenue reaching ₹165.96 crore and annual revenue growth of 115.42 percent. The company maintains an efficient capital profile with a Return on Equity of 32.46 percent. Currently, the stock trades at a TTM P/E of 31.45, which is lower than the industry average P/E of 62.06 and the sector average of 45.34.
While the one-year stock price change reflects a 70.49 percent decline, recent momentum is indicated by a 23.76 percent gain over the last week and a high RSI of 71.72.
Management Vision
With Lung Care Tablets, we are extending this same prevention-led philosophy to respiratory wellness, where smoking, air pollution and environmental exposure are creating an increasingly important health challenge.
| Share price | ₹27.4 |
|---|---|
| Market capitalisation | ₹133.36 Cr |
| Revenue (annual) | ₹155.48 Cr |
| Net profit (annual) | ₹3.98 Cr |
| Revenue (latest quarter) | ₹33.11 Cr-31.60% vs previous quarter |
| Net profit (latest quarter) | ₹1.42 Cr+150.81% vs previous quarter |
| P/E (TTM) | 31.45×Sector 45.34× |
| FII holding | 0%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Aayush Wellness Limited announcing the launch of its new Lung Care Tablets targeting the respiratory healthcare market. Market figures from a third-party data provider.
